{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:22:35Z","timestamp":1791588155965,"version":"4.3.4"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The study was funded by the UK Technology Strategy Board (now called Innovate UK)."}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002230","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T19:52:01Z","timestamp":1487101921000},"page":"e1002230","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":68,"title":["Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service"],"prefix":"10.1371","volume":"14","author":[{"given":"Angela","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wordsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilles M.","family":"Fermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3117-4156","authenticated-orcid":true,"given":"Suzanne","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulvinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kaisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios V.","family":"Vavoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Housby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3037-1470","authenticated-orcid":true,"given":"Ian","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"ref1","unstructured":"National Institute for Health and Care Excellence. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258. London: National Institute for Health and Care Excellence; 2012 [cited 2017 Jan 17]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta258<\/ext-link>."},{"key":"ref2","unstructured":"National Institute for Health and Care Excellence. Cetuximab for the first-line treatment of metastatic colorectal cancer. NICE technology appraisal guidance 176. London: National Institute for Health and Care Excellence; 2009 [cited 2017 Jan 17]. Available from: https:\/\/www.nice.org.uk\/Guidance\/TA176<\/ext-link>."},{"key":"ref3","unstructured":"National Institute for Health and Care Excellence. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269. London: National Institute for Health and Care Excellence; 2012 [cited 2017 Jan 17]. Available from: https:\/\/www.nice.org.uk\/Guidance\/TA269<\/ext-link>."},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"GM Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jmoldx.2013.10.002","article-title":"Validation of a next-generation sequencing assay for clinical molecular oncology","volume":"16","author":"CE Cottrell","year":"2014","journal-title":"J Mol Diagn"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/modpathol.2013.122","article-title":"Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics","volume":"27","author":"R Kanagal-Shamanna","year":"2014","journal-title":"Mod Pathol"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1515\/cclm-2013-0883","article-title":"Routine use of the Ion Torrent AmpliSeq (TM) Cancer Hotspot Panel for identification of clinically actionable somatic mutations","volume":"52","author":"GJ Tsongalis","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-7364-8-9","article-title":"Changing genetic paradigms: creating next-generation genetic databases as tools to understand the emerging complexities of genotype\/phenotype relationships","volume":"8","author":"B Gottlieb","year":"2014","journal-title":"Hum Genomics"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/BIC.S37548","article-title":"The VA Point-of-Care Precision Oncology Program: balancing access with rapid learning in molecular cancer medicine","volume":"8","author":"LD Fiore","year":"2016","journal-title":"Biomark Cancer"},{"issue":"30","key":"ref10","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2010.29.6244","article-title":"Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial","volume":"28","author":"RS Midgley","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/intqhc\/15.1.87","article-title":"Principles for best practice in clinical audit","volume":"15","author":"CD Shaw","year":"2003","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"F Loupakis","year":"2009","journal-title":"Br J Cancer"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.molonc.2014.03.021","article-title":"Standardized decision support in next generation sequencing reports of somatic cancer variants","volume":"8","author":"R Dienstmann","year":"2014","journal-title":"Mol Oncol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-11-0184","article-title":"High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing","volume":"2","author":"N Wagle","year":"2012","journal-title":"Cancer Discov"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.molonc.2014.03.004","article-title":"Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe","volume":"8","author":"HJ Dubbink","year":"2014","journal-title":"Mol Oncol"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"DW-S Wong","year":"2009","journal-title":"Cancer"},{"key":"ref17","unstructured":"National Institute for Health and Care Excellence. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. Technology appraisal guidance 192. London: National Institute for Health and Care Excellence; 2010. Available from: https:\/\/www.nice.org.uk\/guidance\/ta192<\/ext-link>."},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdu054","article-title":"DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma","volume":"25","author":"A Gupta","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ctrv.2014.03.004","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in estrogen receptor-positive breast cancer","volume":"40","author":"EM Ciruelos Gil","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Y Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"ref21","unstructured":"National Institute for Health and Care Excellence. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. Diagnostics guidance 9. London: National Institute for Health and Care Excellence; 2013. Available from: https:\/\/www.nice.org.uk\/guidance\/dg9<\/ext-link>."},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0b013e3182021f3e","article-title":"The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors","volume":"6","author":"RK Kancha","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"26","key":"ref23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"ref24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0959-8049(14)70490-3","article-title":"First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF\/NRAS-mutant melanoma","volume":"50","author":"M Middleton","year":"2014","journal-title":"Eur J Cancer"},{"issue":"12","key":"ref25","first-page":"1198","article-title":"Vemurafenib therapy for stage IV melanoma with V600G-mutation","volume":"11","author":"N Lang","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"GA McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"O Klein","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/1078155214524084","article-title":"Treatment of metastatic melanoma with pazopanib: a report of five patient cases","volume":"21","author":"LE Dayer","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","article-title":"Nilotinib in patients with metastatic melanoma harboring KIT gene aberration","volume":"30","author":"JH Cho","year":"2012","journal-title":"Invest New Drugs"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"R Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"C Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"ref32","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non\u2013small-cell lung cancer in Asia (IPASS)","volume":"29","author":"M Fukuoka","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"31","key":"ref34","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1038\/onc.2008.71","article-title":"EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids","volume":"27","author":"Z Chen","year":"2008","journal-title":"Oncogene"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib","volume":"23","author":"SW Han","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1371\/journal.pmed.0020313","article-title":"Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants","volume":"2","author":"H Greulich","year":"2005","journal-title":"PLoS Med"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BJ20080728","article-title":"Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations","volume":"415","author":"E Avizienyte","year":"2008","journal-title":"Biochem J"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"S Watanabe","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"14","key":"ref39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"E Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"C Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"ref41","article-title":"Analysis of KRAS\/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients","volume":"49","author":"S Stintzing","year":"2013","journal-title":"Eur J Cancer"},{"issue":"29","key":"ref42","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"MC Heinrich","year":"2006","journal-title":"J Clin Oncol"},{"issue":"33","key":"ref43","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"MC Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref44","first-page":"1336","article-title":"Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations","volume":"27","author":"N Sato","year":"2012","journal-title":"Oncol Rep"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/annonc\/mdu255","article-title":"Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"PG Casali","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"ref46","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"DA Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1756-8722-5-60","article-title":"Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma","volume":"5","author":"G Ponti","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"9","key":"ref48","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-13-1591","article-title":"Beyond histology: translating tumor genotypes into clinically effective targeted therapies","volume":"20","author":"CB Meador","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4785","key":"ref49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"DJ Slamon","year":"1987","journal-title":"Science"},{"key":"ref50","unstructured":"FOCUS4. Welcome to FOCUS4. London: Medical Research Council Clinical Trials Unit; 2015 [cited 10 Jan 2017]. Available from: http:\/\/www.focus4trial.org<\/ext-link>."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"g2837","DOI":"10.1136\/bmj.g2837","article-title":"Large personalised medicine trial in lung cancer heralds new research partnership","volume":"348","author":"I Torjesen","year":"2014","journal-title":"BMJ"},{"key":"ref52","unstructured":"Technology Strategy Board. Stratified medicines programme: tumour profiling and data capture to improve cancer care. Competition for collaborative R&D funding. London: Technology Strategy Board; 2011 Jan [cited 10 Jan 2017]. Available from: http:\/\/webarchive.nationalarchives.gov.uk\/20130221185318\/www.innovateuk.org\/_assets\/pdf\/competition-documents\/briefs\/tsb_stratmedtumourprofilingcompetition.pdf<\/ext-link>."},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jmoldx.2016.04.003","article-title":"Health care infrastructure for financially sustainable clinical genomics","volume":"18","author":"JK Lennerz","year":"2016","journal-title":"J Mol Diagn"},{"issue":"18","key":"ref54","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2014.59.3665","article-title":"Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis","volume":"33","author":"CJ Gallego","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/cge.12488","article-title":"Use of panel tests in place of single gene tests in the cancer genetics clinic","volume":"88","author":"A Yorczyk","year":"2015","journal-title":"Clin Genet"},{"issue":"9","key":"ref56","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jmedgenet-2015-103270","article-title":"Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes","volume":"52","author":"I Ghemlas","year":"2015","journal-title":"J Med Genet"},{"issue":"9","key":"ref57","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1373\/clinchem.2012.202390","article-title":"Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates","volume":"59","author":"H Do","year":"2013","journal-title":"Clin Chem"},{"issue":"6","key":"ref58","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cam4.293","article-title":"The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling","volume":"3","author":"A Sankin","year":"2014","journal-title":"Cancer Med"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T12:50:04Z","timestamp":1589028604000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002230"}},"subtitle":[],"editor":[{"given":"Marc","family":"Ladanyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002230","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]}}}